PUBLISHER: DelveInsight | PRODUCT CODE: 1377967
PUBLISHER: DelveInsight | PRODUCT CODE: 1377967
“"Dupilumab Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about dupilumab for bullous pemphigoid in the seven major markets. A detailed picture of the dupilumab for bullous pemphigoid in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the dupilumab for bullous pemphigoid. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the dupilumab market forecast analysis for bullous pemphigoid in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in bullous pemphigoid.
Dupilumab (Dupixent) is a monoclonal antibody targeting the α chain of the interleukin (IL)-4 receptor. It inhibits the biological effects of the cytokines IL-4 and IL-13, which are key drivers in the TH2 response (Sastre, 2018).
Dupilumab is approved in the US to treat patients aged 12 years and older with moderate-to-severe atopic dermatitis (AD) that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies; for use with other asthma medicines for the maintenance treatment of moderate-to-severe eosinophilic or oral steroid-dependent asthma in patients aged 12 years and older whose asthma is not controlled with their current asthma medicines; and for use with other medicines for the maintenance treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP) in adults whose disease is not controlled. In adolescents 12 years of age or older, it is recommended that dupilumab be administered by or under an adult's supervision.
In addition to the currently approved indications, Regeneron and Sanofi are also investigating dupilumab in a broad range of clinical development programs for diseases driven by allergic and other Type 2 inflammation, including peanut allergy, grass allergy, AD in pediatric patients, asthma in pediatric patients, eosinophilic esophagitis, chronic obstructive pulmonary disease (COPD), bullous pemphigoid (BP), prurigo nodularis, chronic spontaneous urticaria, and allergic bronchopulmonary aspergillosis.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
Dupilumab Analytical Perspective by DelveInsight
This report provides a detailed market assessment of dupilumab for bullous pemphigoid in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.
The report provides the clinical trials information of dupilumab for bullous pemphigoid covering trial interventions, trial conditions, trial status, start and completion dates.
Key Questions